-
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
Wednesday, August 25, 2021 - 8:12am | 273Read More...Lipocine Inc (NASDAQ: LPCN) has announced topline 36-week results from its Phase 2 proof of concept LiFT study investigating LPCN 1144 in Non-Alcoholic Steatohepatitis (NASH). LPCN 1144 comprises an orally delivered prodrug of endogenous testosterone (T). At 12 weeks...
-
Siemens' Fatty Liver Disease Blood Test Wins FDA De Novo Clearance
Tuesday, August 24, 2021 - 1:21pm | 228Read More...The FDA has granted clearance to a blood test from Siemens Healthineers (OTC: SMMNY) to provide an easier and potentially more accurate diagnostic alternative than an invasive tissue biopsy for non-alcoholic steatohepatitis (NASH). The agency's de novo green light covers the Advia Centaur...
-
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
Friday, May 7, 2021 - 6:56am | 283Read More...Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced interim data from the Phase 2 trial evaluating its selective cortisol modulator miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). The company had to suspend the trial after most patients...
-
89bio's NASH Candidate Shows Clinically Meaningful Outcomes At ENDO Conference
Monday, March 22, 2021 - 1:16pm | 244Read More...89bio Inc (NASDAQ: ETNB) announced additional data from its Phase 1b/2a study evaluating BIO89-100 in patients with nonalcoholic steatohepatitis (NASH). The company will present the data at the Endocrine Society's annual meeting. BIO89-100 is a glycoPEGylated analog of...
-
A Primer On NASH
Thursday, December 15, 2016 - 10:47am | 357Read More...Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD), a condition in which fat builds up in a person's liver. As noted by the National Institute of Diabetes and Digestive and Kidney Diseases, there are no approved medicines to treat NAFLD and NASH. In a...
